Comparing two drug combinations for PD-L1 positive triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study compares two combinations of drugs for people with a specific type of advanced breast cancer called triple-negative, which is PD-L1 positive. One combination uses sacituzumab govitecan, a targeted drug, with toripalimab, an immunotherapy. The other uses toripalimab with nab-paclitaxel, a chemotherapy. The goal is to see which combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- Your breast cancer is triple-negative, meaning it does not have receptors for estrogen, progesterone, or HER2.
- Your cancer is advanced (unresectable locally advanced or metastatic) and you have not had prior treatment for this stage.
- Your tumor is PD-L1 positive (CPS ≥1), a protein that may make immunotherapy more likely to work.
- You have measurable disease (tumors that can be seen on scans) and are physically active (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—sacituzumab govitecan (a targeted therapy) and Q901 (a study drug that blocks a protein needed for cancer cell growth)—in people with advanced triple-negative breast cancer who have already tried other treatments. The goal is to see if this combination can shrink or control the cancer.
This trial compares two antibody-drug conjugates (targeted cancer-killing drugs) given one after the other to see if they work well for triple-negative breast cancer with low HER2. It aims to provide a new treatment option that may slow the cancer's growth.
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
This trial tests a combination of two drugs—sacituzumab govitecan (a targeted chemotherapy) and toripalimab (an immunotherapy)—as the first treatment for advanced triple-negative breast cancer. The goal is to see if this pair works better than standard treatments, and to look for biomarkers that might predict who benefits most.
This study compares a new combination of drugs (sacituzumab govitecan and pembrolizumab) against standard chemotherapy after you have already had initial chemotherapy. The aim is to see if the new combination shrink more breast cancers before surgery in people with triple-negative breast cancer.
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
Hear when a new Triple Negative Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.